News from pharmaceutical companies and other related healthcare organizations
We often scan the pituitary universe and report on the latest drug developments, new potential therapies, and engaging clinical cases and resources. We hope this knowledge helps people gain more insight into these complicated diseases and the fascinating medical/scientific discovery, research, and diagnosis world.
From Jorge D. Faccinetti, co-founder and chief editor: Why can’t we address some of the most critical issues affecting healthcare today? These are not just other people’s problems. They affect us, our doctors, and our
From the desk of Jorge D. Faccinetti – chief editor and co-founder – I am thrilled to announce that Pituitary World News co-founder Dr. Lewis Blevins has been working on a new book on Cushing’s
Spain and Spanish-speaking countries have been our focus as we seek to develop more content in Spanish for our edition of Pituitary Word News in Español. Today’s podcasts covers part of the conference and shares my conversations with three world-renowned Spanish endocrinologists.
In today’s podcast, we talk with Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, where he leads a team in developing and marketing treatments for rare and ultra-rare diseases.
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
By J D Faccinetti, co-founder – In a three-day conference packed with thousands of scientists, endocrinologists, industry, and researchers, ENDO 2023 Conference presented a comprehensive review of the latest in pituitary disease advances, treatment, management, developments,
Acroline™ is a series of four brochures created by Pfizer in collaboration with an international panel of people with acromegaly, acromegaly support groups, and health psychologists. This series of supportive guides and tools are designed to help keep your life on track and live well with acromegaly.
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
We caught up with Sheila a few weeks ago at the Acromegaly Community Conference near San Francisco. We had a captivating chat about Mycapssa (oral octreotide) and about Amryt’s start in Dublin, Ireland, just six years ago, its philosophy, brand, and plans.
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.